Results 1 to 10 of about 21,764,403 (203)

Summary Workshop Report: Bioequivalence, Biopharmaceutics Classification System, and Beyond [PDF]

open access: yesThe AAPS Journal, 2008
The workshop "Bioequivalence, Biopharmaceutics Classification System, and Beyond" was held May 21-23, 2007 in North Bethesda, MD, USA. This workshop provided an opportunity for pharmaceutical scientists to discuss the FDA guidance on the Biopharmaceutics Classification System (BCS), bioequivalence of oral products, and related FDA initiatives such as ...
James E, Polli   +16 more
exaly   +5 more sources

Caco-2 Cells, Biopharmaceutics Classification System (BCS) and Biowaiter [PDF]

open access: yesActa Medica, 2011
Almost all orally administered drugs are absorbed across the intestinal mucosa. The Caco-2 monolayers are used as an in vitro model to predict drug absorption in humans and to explore mechanism of drug absorption.
Libuše Smetanová   +3 more
doaj   +4 more sources

ICH Guideline for Biopharmaceutics Classification System-Based Biowaiver (M9): Toward Harmonization in Latin American Countries

open access: yesPharmaceutics, 2021
The biopharmaceutical classification system (BCS) is a very important tool to replace the traditional in vivo bioequivalence studies with in vitro dissolution assays during multisource product development.
Claudia Miranda   +6 more
doaj   +2 more sources

Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions [PDF]

open access: yesPharmaceutical Research, 2002
The current BSC guidance issued by the FDA allows for biowaivers based on conservative criteria. Possible new criteria and class boundaries are proposed for additional biowaivers based on the underlying physiology of the gastrointestinal tract. The proposed changes in new class boundaries for solubility and permeability are as follows: 1.
Polli, James E.   +10 more
openaire   +5 more sources

Biowaiver based on biopharmaceutics classification system: Considerations and requirements

open access: yesPharmaceutical Science Advances
Biowaiver allows for the waiver of bioequivalence studies for regulatory approval of certain drug products with saving of time, and money. Before approval of the application for biowaivers, studies based on the Biopharmaceutical Classification System ...
Pratik R. Dhake   +2 more
doaj   +3 more sources

Is the full potential of the biopharmaceutics classification system reached?

open access: yesEuropean Journal of Pharmaceutical Sciences, 2014
In this paper we analyse how the biopharmaceutics classification system (BCS) has been used to date. A survey of the literature resulted in a compilation of 242 compounds for which BCS classes were reported. Of these, 183 compounds had been reported to belong to one specific BCS class whereas 59 compounds had been assigned to multiple BCS classes in ...
Christel A S, Bergström   +4 more
openaire   +4 more sources

Integrated biopharmaceutical approach in pharmaceutical development and drug characterization: General concept and application [PDF]

open access: yesHemijska Industrija, 2020
The importance of biopharmaceutical considerations in pharmaceutical development and drug characterization has been well recognized both by pharmaceutical industry and regulatory authorities as a tool to establish predictive relationships ...
Cvijić Sandra V.   +2 more
doaj   +1 more source

An Overview on Dietary Polyphenols and Their Biopharmaceutical Classification System (BCS) [PDF]

open access: yesInternational Journal of Molecular Sciences, 2021
Polyphenols are natural organic compounds produced by plants, acting as antioxidants by reacting with ROS. These compounds are widely consumed in daily diet and many studies report several benefits to human health thanks to their bioavailability in humans. However, the digestion process of phenolic compounds is still not completely clear.
Truzzi F.   +4 more
openaire   +2 more sources

Comparator product issues for biowaiver implementation: the case of Fluconazole

open access: yesBrazilian Journal of Pharmaceutical Sciences, 2022
The aim of this work was to assess if the commercially available Fluconazole drug products (Reference, Generic and Similar) would meet the biowaiver criteria from Food and Drug Administration (FDA) and Brazilian Agency for Health Surveillance (ANVISA ...
Raul Edison Luna Lazo   +8 more
doaj   +1 more source

Development of Extended-Release Mini-Tablets Containing Metoprolol Supported by Design of Experiments and Physiologically Based Biopharmaceutics Modeling

open access: yesPharmaceutics, 2022
The development of extended-release dosage forms with adequate drug release is a challenge for pharmaceutical companies, mainly when the drug presents high solubility, as in Biopharmaceutics Classification System (BCS) class I.
Michele Georges Issa   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy